Baxter International Inc
 (BAX)

- NYSE
What's your position on ?
Bullish
Bearish
Why are you ish?
Skip
Post
You voted ish on Vote again
Posts appear on the My Feed page of subscribers to this ticker
Last vote:
  • Apr. 17, 2014, 7:02 AM
    • Baxter (BAX): Q1 EPS of $1.19 beats by $0.11.
    • Revenue of $3.95B (+14.5% Y/Y) beats by $70M.
    | Apr. 17, 2014, 7:02 AM
  • Apr. 17, 2014, 12:05 AM
    | Apr. 17, 2014, 12:05 AM
  • Apr. 16, 2014, 5:30 PM
    | Apr. 16, 2014, 5:30 PM | 1 Comment
  • Apr. 16, 2014, 9:28 AM
    • Baxter International's (BAX) BAX 111 treatment met the primary endpoint in a Phase III trial of patients with von Willebrand disease, the most common type of inherited bleeding disorder.
    • BAX 111 successfully treated 22 patients who experienced bleeding episodes during the trial.
    • Secondary endpoints included those related to additional efficacy and safety measures, pharmacokinetics and health-related quality of life.
    • Shares are +1.55% premarket. (PR)
    | Apr. 16, 2014, 9:28 AM
  • Mar. 27, 2014, 9:11 AM
    | Mar. 27, 2014, 9:11 AM | 2 Comments
  • Mar. 27, 2014, 8:08 AM
    • Baxter International (BAX) is splitting into two companies, with one focused on biopharmaceuticals and the other on medical products.
    • Baxter will make a tax-free distribution of shares in the biopharmaceuticals business to its shareholders. The company expects to complete the transaction by mid-2015.
    • The biopharmaceuticals business generated 2013 annual revenues of $6B and develops treatments for hemophilia and other bleeding disorders, immune deficiencies, burns and shock.
    • The medical-products business earned annual sales of over $9B and provides intravenous (IV) solutions and nutritional therapies, drug-delivery systems and administration sets, and premixed and other injectable drugs, as well as inhalation anesthetics and hospital-based biosurgery products.
    • Baxter CEO Robert Parkinson will head the medical-products company, which will retain the Baxter International name.
    • Ludwig Hantson, who is president of BioScience, will run the biopharmaceuticals firm. (PR)
    • Shares are +12.5%.
    | Mar. 27, 2014, 8:08 AM | 15 Comments
  • Mar. 26, 2014, 12:27 PM
    • Baxter (BAX) hires Goldman Sachs to help find a buyer for its $300M vaccines business that includes vaccines for meningitis C and tick-borne encephalitis.
    • The company's move is another example of a large healthcare firm trying to divest non-core assets.
    | Mar. 26, 2014, 12:27 PM | 1 Comment
  • Mar. 26, 2014, 8:33 AM
    • Large cap pharma and biotech firms have regenerative therapy R&D programs underway according to a recent survey.
    • 69% of respondents are focused on developing cellular-based therapies.
    • Wound healing and burns have the greatest near-term potential.
    • Long term areas of interest are cardiovascular disease, oncology, neurodegenerative disease, monogenic disorders and ocular disease.
    • (AGN) (AMGN) (BAX) (BIIB) (CELG) (LLY) (GSK) (JNJ) (NVS) (NVO) (PFE) (RHHBY) (SNY) (MRK) (SHPG)
    | Mar. 26, 2014, 8:33 AM | 2 Comments
  • Mar. 17, 2014, 10:23 AM
    • Goldman Sachs removes Baxter International (BAX) from its Conviction List and lowers its PT from $83 to $77 but maintains its Buy recommendation. Since the firm added BAX to its Americas CL in August it is off 7.7% versus the S&P 500's 8.5% gain.
    • Analyst David Roman cites a higher risk profile due to heightened competition in the plasma business.
    • Investors appear unconcerned. Shares are up a fraction in early trading.
    | Mar. 17, 2014, 10:23 AM | 1 Comment
  • Mar. 4, 2014, 4:49 PM
    • Cell Therapeutics (CTIC) Q4 revenue balloons to $32.9M versus $0 a year ago. Almost all of the revenue is due to Baxter's (BAX) upfront payment of $32.4M for the license to develop and commercialize pacritinib.
    • Product revenues for Q4 and FY13 were $.5M and $2.3M, respectively.
    • Net income for the quarter was $10.2M ($.08/share) due to the Baxter payment. Net loss for the year was $49.6M ($.43/share).
    • FY14 guidance projects a loss from operations of $45M - $50M.
    • Consensus estimate for Q1 is a loss of $.23/share on revenues of $1.3M.
    • Consensus estimate for 2014 is a loss of $.48/share on revenues of $23.9M.
    • Mutual fund ownership has increased from 30 to 85 the past 4 quarters.
    | Mar. 4, 2014, 4:49 PM | 1 Comment
  • Feb. 18, 2014, 9:28 AM
    • Baxter International Inc (BAX) declares $0.49/share quarterly dividend, in line with previous.
    • Forward yield 2.84%
    • Payable April 1; for shareholders of record March 7; ex-div March 5.
    | Feb. 18, 2014, 9:28 AM
  • Jan. 23, 2014, 8:45 AM
    • Baxter (BAX) net profit -34% to $326M, hurt by expenses related to its $4B acquisition of Swedish dialysis product manufacturer Gambro, collaborations and other items.
    • Gross margin dropped to 44.7% from 50.8%
    • Sales breakdown: medical products +25% to $2.59B, including $413M from Gambro. Bioscience +5% to $1.78B, mainly boosted by solid demand for Baxter's hemophilia treatments.
    • Guidance: Q1 adjusted EPS $1.06-1.09 vs consensus of $1.14; 2014 EPS $5.05-5.25 vs $5. (PR)
    • Previous
    | Jan. 23, 2014, 8:45 AM
  • Jan. 23, 2014, 7:02 AM
    • Baxter International Inc (BAX): Q4 EPS of $1.26 beats by $0.01.
    • Revenue of $4.4B (+15.8% Y/Y) beats by $150M.
    | Jan. 23, 2014, 7:02 AM
  • Jan. 23, 2014, 12:05 AM
  • Jan. 22, 2014, 5:30 PM
    | Jan. 22, 2014, 5:30 PM | 7 Comments
  • Jan. 7, 2014, 9:25 AM
    • RBC cuts Baxter (BAX) to Sector Perform from Outperform.
    • Price target is $73.
    | Jan. 7, 2014, 9:25 AM | 2 Comments
Company Description
Baxter International Inc is a healthcare company. It develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma and other chronic conditions.